Bafna Pharmaceuticals Limited

Operating margins have collapsed from 14.64% (Jun 2025) to 3.31% (Jun 2026), a 77% decline; verify whether this reflects temporary cost inflation, pricing pressure, or structural loss of competitive positioning.

Revenue is volatile—ranging ₹26.58–₹42.24 crore over eight quarters, with the latest quarter at the lowest point. Clarify if this reflects seasonality, customer concentration, product delays, or demand loss.

Valuation has stretched on 216.66% one-year returns; PE of 147.17 with ROE of only 5.01% leaves minimal margin for error if recovery does not materialise.

Domestic institutional investors hold zero stake despite the company's market size; verify whether this reflects known governance, operational, or sector concerns.

Operating margins recovered to 14.64% (Jun 2025) before collapsing to 3.31% (Jun 2026); restoration is possible if cost pressures ease—verify drivers of recent decline and management's remediation plan.

Low debt (D/E 0.33) enables balance-sheet-funded capacity expansion or M&A if pursued; verify capex intensity and any growth strategy.

Indian pharma sector benefits from rising healthcare consumption and generic penetration; verify company's therapeutic focus and export footprint.